Gynecological
Most recent
New Phase III Data on Bevacizumab for the Treatment of Newly Diagnosed, Advanced, and Recurrent Ovarian Cancer
NE Oncology Issue - September 2011 Ovarian Cancer Among ovarian cancers, surgery to remove as much of the tumour as possible is a mainstay of treatment but unfortunately, the majority of patients are diagnosed with advanced disease and require further treatment....
OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
NE Oncology Issue - September 2011 Background Results from the OCEANS trial build on findings from two previous phase III studies in newly diagnosed ovarian cancer, GOG 0218 and ICON7.1,2 Both of these studies showed that front-line bevacizumab in combination with...
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer
NE Oncology Issue - September 2011 Background In 2006, the Gynecologic Cancer InterGroup (GCIG) ICON7 study — a multicenter, phase III randomized trial — was launched and designed to investigate the safety and efficacy of adding bevacizumab to standard chemotherapy in...
Independent radiologic review of GOG218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal or fallopian tube cancer
NE Oncology Issue - September 2011 Background The Gynecologic Oncology Group (GOG) 218 is a phase III, randomized, double-blind, placebo-controlled trial with three arms comparing placebo in combination with carboplatin and paclitaxel (CP) chemotherapy followed by...
Twitter feed